Resumen de Análisis farmacoeconomico del tratamiento de la artrosis con condroitín sulfato en comparación con aine
Carlos Rubio Terrés, Ingrid Möller, E. T. Campeny, Josep Vergés Milano
Objective: To compare the efficiency of several pharmacologic treatments (chondroitin sulfate, CS; diclophenac sodium, DS; ibuprofen, IB; celecoxib, CC; or rofecoxib, RC) in Spanish patients affected by arthrosis. Methods: Cost-minimization model that compared treatments, administrated with the recommended dosage and patterns, for a six-month period. The use of resources and the unit costs were estimated from metaanalysis of randomized clinical trials. Simple univariant sensitivity analyses of basic case were performed. Results: The cost per semester per treated patient with CS, DS, IB, CC or RC was estimated in 85.88 euros , 96.42 euros, 88.27 euros 270.68 euros and 285.93 euros, respectively. In the treatment with CS of a hypothetical cohort of 10,000 patients with arthrosis, the National Health System could save between 23,900 euros and 2,000,500 euros per semester, in comparison to alternative treatments. Furthermore, numerous cases of gastrointestinal adverse effects would be avoided in total (1, 782 to 2, 730) and grave (17 to 90), as well as possible myocardial infarctions (5 to 29). The sensitivity analysis confirmed the stability of the basic case in the large majority of the cases being considered. Conclusions: Chondroitin sulfate is a more efficient treatment for arthrosis, with lower costs and a better gastrointestinal tolerance, than diclophenac sodium, ibuprofen, celecoxib or rofecoxib
